"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A,US 5008252 A,009-259-327-040-902,1991-04-16,1991,US 2850787 A,1987-03-20,US 2850787 A,1987-03-20,Process for inhibiting herpes simplex virus-specified thymidine kinase,The invention relates to a method of selectively inhibiting herpes simplex virus-specified thymidine kinase. The method comprises exposing mammalian cells infected with the virus to an effective amount of 5'-ethynylthymidine. The invention further relates to a pharmaceutical composition comprising 5'-ethynylthymidine as the active ingredient together with a pharmaceutically acceptable carrier.,UNIV NORTH CAROLINA;;HEALTH RESEARCH INC,CHENG YUNG-CHI;;BOBEK MIROSLAV,UNIVERSITY OF NORTH CAROLINA THE CHAPEL HILL (1987-05-27);;HEALTH RESEARCH INC (1987-05-04),https://lens.org/009-259-327-040-902,Granted Patent,yes,2,3,1,1,0,A61K31/045;;A61K31/70;;A61K31/70;;A61K31/045,A61K31/045,514/50;;514/729;;514/934,2,1,061-207-707-392-847,621599;;10.1021/jo00396a051,"Sharma et al., J. Org. Chem. 43, No. 2, pp. 367 369 (1978).;;Nutter et al., the Chemical Abstracts 106:188509g (1987).",EXPIRED
2,US,A,US 4321366 A,150-585-165-005-287,1982-03-23,1982,US 15620280 A,1980-06-03,US 15620280 A;;US 90552978 A,1978-05-12,Process of preparing 2-azido-2-deoxyarabinofuranosyl halides,"Novel arabinofuranosyl nucleosides and nucleotides having 2'-azido,2'-amino, or 2'-hydrocarbylamino substituents, which have antitumor, antiviral, and antimicrobial properties, are prepared by condensation of a pyrimidine, purine, or 1,3-oxazine base with an acylated 2-azido-2-deoxyarabinofuranosyl halide, followed by deblocking and catalytic hydrogenation, where appropriate, to convert the 2'-azido group to a 2'-amino group and, if desired, alkylation or the like to convert the 2'-amino group to a 2'-hydrocarbylamino group.",RESEARCH CORP,BOBEK MIROSLAV V;;BLOCH ALEXANDER;;CHENG YUNG-CHI,,https://lens.org/150-585-165-005-287,Granted Patent,yes,4,12,1,11,0,C07H9/04;;C07H9/04;;C07H11/00;;C07H11/00;;C07H19/06;;C07H19/06;;C07H19/16;;C07H19/16,C07H9/04;;C07H11/00;;C07H19/06;;C07H19/16,536/55,0,0,,,,EXPIRED
3,US,A,US 4230698 A,062-915-921-572-121,1980-10-28,1980,US 90552978 A,1978-05-12,US 90552978 A,1978-05-12,2-Substituted arabinofuranosyl nucleosides and nucleotides,"Novel arabinofuranosyl nucleosides and nucleotides having 2'-azido, 2'-amino, or 2'-hydrocarbylamino substituents, which have antitumor, antiviral, and antimicrobial properties, are prepared by condensation of a pyrimidine, purine, or 1,3-oxazine base with an acylated 2-azido-2-deoxyarabinofuranosyl halide, followed by deblocking and catalytic hydrogenation, where appropriate, to convert the 2'-azido group to a 2'-amino group and, if desired, alkylation or the like to convert the 2'-amino group to a 2'-hydrocarbylamino group.",RESEARCH CORP,BOBEK MIROSLAV V;;BLOCH ALEXANDER;;CHENG YUNG-CHI,,https://lens.org/062-915-921-572-121,Granted Patent,yes,5,36,10,11,0,C07H9/04;;C07H19/06;;C07H19/16;;A61P31/12;;C07H9/04;;C07H19/16;;C07H19/06,A61K31/70;;A61K31/7008;;A61K31/7042;;A61K31/7052;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/12;;C07H5/04;;C07H9/04;;C07H19/06;;C07H19/10;;C07H19/16;;C07H19/20,424/180,2,2,044-401-330-456-320;;097-978-241-620-36X,6043946;;10.1021/jo01283a037;;10.1016/s0040-4039(01)83514-0,"Reist, E., et al. J. Organic Chemistry, vol. 32, 2538-2541 (1967).;;Unger et al., Tetrahedron Letters, No. 50, pp. 4383-4384 (1977).",EXPIRED
4,EP,A4,EP 0016005 A4,138-718-058-303-272,1980-05-21,1980,EP 79900566 A,1979-12-17,US 90552978 A,1978-05-12,"2'-SUBSTITUTED BETA-ARABINOFURANOSYL NUCLEOSIDES AND NUCLEOTIDES, PREPARATION AND USE THEREOF.",,RESEARCH CORP,BOBEK MIROSLAV V;;BLOCH ALEXANDER;;CHENG YUNG-CHI,,https://lens.org/138-718-058-303-272,Search Report,no,1,0,10,11,0,C07H9/04;;C07H19/06;;C07H19/16;;A61P31/12;;C07H9/04;;C07H19/16;;C07H19/06,A61K31/70;;A61K31/7008;;A61K31/7042;;A61K31/7052;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/12;;C07H5/04;;C07H9/04;;C07H19/06;;C07H19/10;;C07H19/16;;C07H19/20,,5,4,044-401-330-456-320;;043-823-778-626-643;;054-018-506-657-697;;039-204-433-784-227,6043946;;10.1021/jo01283a037;;10.1021/jm00211a023;;833809;;10.1016/s0040-4039(01)94709-4;;276611;;10.1021/jm00205a001,"THE JOURNAL OF ORGANIC CHEMISTRY, Vol. 32, No. 8, August 1967, pages 2538-2541, Mack Printing Co., Easton, Pennsylvania, U.S.A., E.J. REIST et al.: ""Some reactions of 9-(2,3-Anhydro-5-deoxy-beta-D-pentofuranosyl) adenines"".;;JOURNAL OF MEDICINAL CHEMISTRY, Vol. 20, 1977, pages 113-116, American Chemical Society, D.H. HOLLENBERG et al.: ""Nucleosides. 102. Synthesis of Some 3'-Deoxy-3'-Substituted Arabino-furanosylpyrimidine Nucleosides"".;;CHEMICAL ABSTRACTS, vol. 90, no. 13, 26th March 1979, page 629, no. 104310a, Columbus, Ohio, USA, & JP - A - 53 121793 (KYOWA HAKKO KOGYO CO., LTD.) 24-10-1978;;TETRAHEDRON LETTERS, no. 22, May 1978, pages 1919 - 1922, Pergamon Press: Oxford, M. BOBEK: 'The synthesis of anomeric 3-0-acetyl-5-0-benzoyl-2-azido-2-deoxy-D-arabinofuranosyl chlorides. Versatile sugar intermediates for the synthesis of 2'-azido-2'-deoxy- and 2'-amino-2'-deoxy-béta-D-arabinofuranosyl nucleosides';;JOURNAL OF MEDICINAL CHEMISTRY, vol. 21, no. 7, July 1978, pages 597 - 598, American Chemical Society, M. BOBEK: 'Novel Arabinofuranosyl Derivatives of Cytosine Resistant to Enzymatic Deamination and Possessing Potent Antitumor Activity'",EXPIRED
5,EP,B1,EP 0016005 B1,176-788-659-131-340,1984-07-25,1984,EP 79900566 A,1979-12-17,US 90552978 A,1978-05-12,"2'-SUBSTITUTED BETA-ARABINOFURANOSYL NUCLEOSIDES AND NUCLEOTIDES, PREPARATION AND USE THEREOF",,RESEARCH CORPORATION,"BOBEK, MIROSLAV V.;;BLOCH, ALEXANDER;;CHENG, YUNG-CHI",,https://lens.org/176-788-659-131-340,Granted Patent,yes,0,0,10,11,0,C07H9/04;;C07H19/06;;C07H19/16;;A61P31/12;;C07H9/04;;C07H19/16;;C07H19/06,A61K31/70;;A61K31/7008;;A61K31/7042;;A61K31/7052;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/12;;C07H5/04;;C07H9/04;;C07H19/06;;C07H19/10;;C07H19/16;;C07H19/20,,2,1,069-488-036-767-066,10.1016/s0008-6215(00)81922-9,"Chemical Abstracts, Volume 87, No. 25, issued 1977, December 19, (Columbus, Ohio, U.S.A.), Buchanan et al., ""Action of ammonia on the methyl 2,3-anhydro-D-ribofuranosides and treatment of the products with nitrous acid"". See page 767, column 2, the Abstract No. 201957n, Carbohydr. Res. 1977, 57, 85-93 (Eng.);;""The Carbohydrates (Chemistry and Biochemistry)"", Academic Press (1970), Vol IIA, Pigman + Horton, pages 9-21",EXPIRED
6,DE,D1,DE 2967128 D1,009-326-748-827-479,1984-08-30,1984,DE 2967128 T,1979-05-14,US 90552978 A;;US 7900325 W,1978-05-12,"2'-SUBSTITUTED BETA-ARABINOFURANOSYL NUCLEOSIDES AND NUCLEOTIDES, PREPARATION AND USE THEREOF",,RESEARCH CORP,BOBEK MIROSLAV V;;BLOCH ALEXANDER;;CHENG YUNG-CHI,,https://lens.org/009-326-748-827-479,Granted Patent,no,0,0,10,11,0,C07H9/04;;C07H19/06;;C07H19/16;;A61P31/12;;C07H9/04;;C07H19/16;;C07H19/06,A61K31/70;;A61K31/7008;;A61K31/7042;;A61K31/7052;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/12;;C07H5/04;;C07H9/04;;C07H19/06;;C07H19/10;;C07H19/16;;C07H19/20,,0,0,,,,EXPIRED
7,EP,A1,EP 0016005 A1,117-132-172-748-97X,1980-10-01,1980,EP 79900566 A,1979-12-17,US 90552978 A,1978-05-12,"2'-SUBSTITUTED BETA-ARABINOFURANOSYL NUCLEOSIDES AND NUCLEOTIDES, PREPARATION AND USE THEREOF.","Des nucleosides et des nucleotides d'arabinofuranosyle nouveaux avec des substituants 2'-azido, 2'-amino ou 2'-hydrocarbylamino ayant des proprietes antitumorales, antivirales et antimicrobiennes sont prepares par condensation d'une base de pyrimidine, purine ou 1,3-oxazine avec un halogenure de 2-azido-2-deoxyarabino-furanosyle acyle suivi par un deblocage et une hydrogenation catalytique, si necessaire, pour convertir le groupe 2'-azido en un groupe 2'-amino et, si l'on veut, par une alkylation ou un autre procede semblable pour convertir le groupe 2'-amino en un groupe 2'-hydrocarbylamino.",RESEARCH CORP,BOBEK MIROSLAV V;;BLOCH ALEXANDER;;CHENG YUNG-CHI,,https://lens.org/117-132-172-748-97X,Patent Application,no,0,0,10,11,0,C07H9/04;;C07H19/06;;C07H19/16;;A61P31/12;;C07H9/04;;C07H19/16;;C07H19/06,A61K31/70;;A61K31/7008;;A61K31/7042;;A61K31/7052;;A61K31/7064;;A61K31/7068;;A61K31/7072;;A61K31/7076;;A61K31/708;;A61P31/12;;C07H5/04;;C07H9/04;;C07H19/06;;C07H19/10;;C07H19/16;;C07H19/20,,0,0,,,,EXPIRED
8,US,A,US 4918056 A,077-459-336-167-289,1990-04-17,1990,US 91837286 A,1986-10-14,US 91837286 A,1986-10-14,2-substituted arabinopyranosyl nucleosides and nucleotides,"Novel arabinopyranosyl nucleoside derivatives having the heterocyclic moiety and fluorine at the 2' position of the sugar ring (pyranose configuration), which have antitumor, antiviral and antimicrobial properties, are prepared by condensation of a pyrimidine, purine or 1,3-oxazine base with an acylated 2-deoxy-2,2-difluoro-D-arabinopyranoside and/or acylated 2-deoxy-2-bromo-2-fluoro-D-arabinopyranoside.",HEALTH RESEARCH INC ROSWELL PA,BOBEK MIROSLAV V;;AN SEUNG-HO;;BERNACKI RALPH J,HEALTH RESEARCH INC (1986-10-02),https://lens.org/077-459-336-167-289,Granted Patent,yes,1,7,1,1,0,C07H19/06;;C07H19/06;;C07H19/16;;C07H19/16;;C07H19/24;;C07H19/24,C07H19/06;;C07H19/16;;C07H19/24,514/25;;514/50;;536/4.1;;536/17.3;;536/18.1;;536/18.4;;536/23;;536/24;;536/120;;536/122,17,8,093-325-943-504-212;;087-165-664-891-267;;032-620-163-310-221;;030-443-704-401-939;;151-352-986-979-686;;045-492-255-787-156;;042-460-327-831-211;;022-127-420-583-027,10.1248/cpb.33.1652;;2931191;;10.1021/jo01017a007;;10.1021/jo00443a033;;13663029;;10.1021/jm00191a028;;379335;;10.1093/jnci/10.1.179;;18143260;;10.1080/00401706.1964.10490181;;10.1002/art.10697;;10.1016/s0169-5002(86)80023-x;;12528101;;10.1515/9781400857913.45a;;10.1016/s0169-5002(86)80705-x,"Ho et al, Chemical Abstracts, 105: 209314m (1986).;;Kawaguchi et al, Chem. Pharm. Bull. 33(4) 1652 1659 (1985).;;Narayanan et al, J. Org. Chem., 30 1734 1736 (1965).;;Jung et al, J. Org. Chem. 42 (23) pp. 3761 3763 (1977).;;Montgomery, Cancer Research 19(5), pp. 447 463 (1959).;;Bobek et al, J. Med. Chem. 22 pp. 592 597 (1979).;;British Publication Tetrahed. Lett. 39: 3433 3436 (1977).;;Kierzek, R. et al.: Tetrahed. Lett. 22: 3761 (1981).;;E. Law et al., J. National Cancer Institute 10: 179 192, (1949).;;National Cancer Institute (NCI) protocol 3LE31, described IN Vivo Cancer Models, NIH Publication 84 2635, Feb. 1984.;;Cox, D. R. Journal Royal Stat, Soc, Series B 34: 187 220 (1972).;;Dunn, O. J., Technometrics, 6: 241 252, 1964.;;Bernacki et al.; Cancer Research 45: 695, 1985.;;Bergstrom et al., Synthesis of Gem Difluoro Substituted Nucleoside Analogs, Abstract from mtg of American Chemical Society, 1985.;;Grindey et al., Antitumor Activity of 2 ,2 difluorodeoxycytidine, Proceedings of AACR, vol. 27, Mar. 1986.;;Kroin et al., A Practical Synthesis of 2 deoxy 2 2 difluoro D Ribofuranosyl Nucleosides, Abstract from mtg of American Chemical Society, 1986.;;Hertel et al., A Simple and Stereocontrolled Synthesis of 2 Deoxy 2,2 Defluoro D Ribose, Abstract from mtg of American Chemical Society, 1986.",EXPIRED
